Multiple growth drivers across the portfolio

To drive continued growth we focus on commercial excellence.

Genetic Diseases

- Growth in FIRAZYR and LSD portfolio primarily due to an increase in number of patients on therapy
- Increase to the number of patients on therapy with CINRYZE

elaprase®

REPLAGAL®

firazyr®

CINRYZE®

VPRIV®

Neuroscience

- VYVANSE continues to perform strongly, with growth driven by increased use in adults in the U.S., pricing improvement, and continued growth in international markets
- New Drug Application for SHP465 for treatment of ADHD re-submitted to FDA with decision anticipated mid-2017

Vyvanse®

ONE DOSE DAILY ADDERALL XR®

intuniv®

Hematology

- ADYNOVATE label in the U.S. expanded to include children under 12 and use in surgical settings
- First and only registered medical device (myPKFit) to enable personalization of ADVATE prophylaxis
- Launched VONVENDI in the U.S., the only recombinant treatment for adults with von Willebrand disease

ADYNOVATE®

FEIBA®

ADVATE®

my PK FiT®

vonvendi®

Genetic Diseases

Sales

$2,698m

+12%

2015: $2,399m

Neuroscience

Sales

$2,490m

+13%

2015: $2,200m

Hematology[1]

Sales

$2,241m

Ophthalmology

Sales

$54m

Internal Medicine

- LIALDA sales benefiting from continued market share growth
- Growth from an increase in new patients on GATTEX/ REVESTIVE and NATPARA

Lialda · mezavant · Gattex · Revestive · Natpar

Immunology

- HYQVIA continues to add new patients and was approved in 33 countries as of December 31, 2016
- CUVITRU, subcutaneous immune globulin replacement therapy launched in the U.S. in November. International launches to follow in 2017

HyQvia · GAMMAGARD LIQUID · Cuvitru

Oncology

- ONCASPAR continues to perform well in the U.S.; further growth expected internationally, as commercial launches are initiated across EU
- ONIVYDE granted approval in the EU for the treatment of patients with metastatic adenocarcinoma of the pancreas. Launched in first two markets in 2016 with additional countries to follow in 2017

oncaspar · onivyde

Ophthalmology

- Positive contribution from XIIDRA since August 2016, with strong early prescription trends and market share gains, as well as increasing levels of managed care access
- Regulatory submission made in Canada

xiidra

Internal Medicine

Sales

$1,756m

+17%

2015: $1,501m

Immunology[1]

Sales

$1,516m

Oncology[1]

Sales

$131m

[1] Therapeutic area acquired with Baxalta on June 3, 2016.

Shaping future treatments

Innovation is the lifeblood of our current and future success — we now have 37 programs in the clinic with 21 in the later stages of development, with a significant focus on areas of high unmet medical need and rare disease patient populations.


35+


6


10

Preclinical

At this initial stage, the focus is on researching the feasibility and safety of a potential new product. This lays the foundation for clinical trials. We currently have 35+ preclinical research programs underway.

- Internally developed and via partnership
- Both rare disease and specialty conditions
- Multiple modalities including new chemical entities, Monoclonal antibodies, proteins, and gene therapy

Key

● Rare indication
✳ Non-rare indication

[1] Phase 3 expected to start in 2017
[2] Phase 2/3 programs shown as Phase 3

Phase 1

This stage is typically the first time a medicine is tested on humans. The emphasis is on examining effectiveness, side effects and safety. We currently have six programs in Phase 1.

- ● **SHP611**
  MLD
- ● **SHP622**
  Friedreich's Ataxia
- ● **SHP623**
  Neuromyelitis optica
- ● **SHP631:** neurocognitive decline associated with Hunter syndrome
- ● **SHP655**
  Hereditary thrombotic thrombocytopenic purpura
- ● **SHP656**
  Hemophilia A

Phase 2

In Phase 2 we carry out further clinical trials, continuing to investigate efficacy and safety and deepening our understanding, for example of dosage levels. We currently have 10 programs in Phase 2.

- ● **ONIVYDE**
  First-line pancreatic cancer
- ● **ONIVYDE (Japan)**
  Pancreatic cancer post-gemicitabine
- ● **SHP607**
  Complications of prematurity
- ● **SHP625**
  Alagille syndrome ("ALGS")
- ● **SHP625 (PFIC)**
  Progressive familial intrahepatic cholestasis
- ✳ **SHP626**
  Nonalcoholic steatohepatitis ("NASH")
- ✳ **SHP640**[1]
  Infectious conjunctivitis
- ✳ **SHP647**[1]
  Crohn's disease
- ✳ **SHP647**[1]
  Ulcerative colitis
- ✳ **SHP652**
  Systemic lupus erythematosus

17

Phase 3

This is the final stage of clinical trials before registration. It focuses on confirming the effectiveness and safety of the product compared to a placebo or another treatment. We currently have 17 Phase 3 programs.

- **GLASSIA**
  Acute Graft vs. Host Disease
- **Calaspargase pegol**
  Acute lymphoblastic leukemia
- **CINRYZE**
  Antibody Mediated Rejection
- **CINRYZE (Japan)**
  HAE prophylaxis
- **CINRYZE SC**
  HAE prophylaxis
- **FIRAZYR (Japan)**[2]
  Acute HAE
- **GATTEX (Japan)**
  Short bowel syndrome
- **HYQVIA + KIOVIG:** chronic inflammatory Demyelinating polyneuropathy
- **OBIZUR**
  CHAWI surgery
- **OBIZUR (CHAWI on demand)**
  Hemophilia A with inhibitors
- ✳ **SHP555 (U.S.)**
  Chronic constipation
- **SHP609**[2]
  Hunter Syndrome — intrathecal delivery
- **SHP620**
  Cytomegalovirus infection
- **SHP621**
  Eosinophilic esophagitis
- **SHP643**
  Hereditary angioedema prophylaxis
- **VONVENDI (EU)**
  Von Willebrand disease
- ✳ **VYVANSE (Japan)**[2]
  ADHD

4

Registration

Building on the data and understanding gained during the earlier phases, the focus here is on filing for regulatory approval from the relevant authorities. We currently have four programs at this stage of our pipeline.

- **ADYNOVATE (EU)**
  Hemophilia A
- ✳ **INTUNIV (Japan)**
  ADHD
- **NATPAR (EU)**
  Hypoparathroidism
- ✳ **SHP465**
  ADHD



Upcoming milestones

Some of the key anticipated events that we expect in 2017.

NATPAR
EU Filing

INTUNIV
Anticipated Japan Approval*

VYVANSE (Japan)
Filing

NATPAR
Anticipated EU Approval*

SHP643 (HAE)
Phase 3 Data

FIRAZYR (Japan)
Filing

SHP656 (BAX826)
Proof of Concept

SHP611 MLD
Top line Phase 1/2 Data

VONVENDI
EU Filing

SHP465
Anticipated U.S. Approval*

ADYNOVI
Anticipated EU Approval*

Calaspargase pegol (ALL)
BLA Filing

XIIDRA
EU Filing

ONIVYDE (Japan)
Top line data

Hunter IT
Phase 3 data

* Subject to regulatory approval